Abstract

Background: Anemia is common among end-stage renal disease (ESRD) patients who undergone hemodialysis. The total reduction of red blood cell (RBC) count is associated with poor prognosis in these patients. Although erythropoietin (EPO) has been used as an effective treatment for ESRD patients with anemia, a large number of patients still present poor responses to EPO treatment. Methods: We measured T-cell receptor sequencing profiles, including length of complementarity-deteremining region 3 (CDR3), intra- and inter-group (EPO resistant vs. responsive) clonotype diversity, V(D)J usage profiles and V-J combinations from ESRD patients and to investigate the correlation between these features and EPO treatment efficacy. Results: Our results revealed statistical significance in the top 3 ~ 15 most abundant joint distributions of Vβ/Jβ among the two groups, suggesting the importance of V or J gene utilization in the EPO response of ESRD patients. Conclusions: In summary, we provided evidence addressing the potential correlation between the immune repertoire and EPO response in ESRD patients. Trial registration: TMU-JIRB 201309026. Registered 16 October 2013.

Original languageEnglish
Article number43
JournalJournal of Biomedical Science
Volume24
Issue number1
DOIs
Publication statusPublished - Jul 11 2017

Fingerprint

Erythropoietin
T-Cell Antigen Receptor
Chronic Kidney Failure
Anemia
Erythrocyte Count
Blood
Genes
Renal Dialysis
Cells
Therapeutics

Keywords

  • End-stage renal disease
  • Erythropoietin treatment
  • High-throughput sequencing
  • T-cell receptor repertoire

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Molecular Biology
  • Clinical Biochemistry
  • Cell Biology
  • Biochemistry, medical
  • Pharmacology (medical)

Cite this

V-J combinations of T-cell receptor predict responses to erythropoietin in end-stage renal disease patients. / Chang, Wei Chiao; Wong, Henry Sung Ching; Chang, Che Mai; Kao, Chih Chin; Hsu, Yu Wen; Liu, Xiao; Chang, Wen Chang; Wu, Mai Szu.

In: Journal of Biomedical Science, Vol. 24, No. 1, 43, 11.07.2017.

Research output: Contribution to journalArticle

@article{2a5fb5547a5b4b7b97da8b1644bdc5bf,
title = "V-J combinations of T-cell receptor predict responses to erythropoietin in end-stage renal disease patients",
abstract = "Background: Anemia is common among end-stage renal disease (ESRD) patients who undergone hemodialysis. The total reduction of red blood cell (RBC) count is associated with poor prognosis in these patients. Although erythropoietin (EPO) has been used as an effective treatment for ESRD patients with anemia, a large number of patients still present poor responses to EPO treatment. Methods: We measured T-cell receptor sequencing profiles, including length of complementarity-deteremining region 3 (CDR3), intra- and inter-group (EPO resistant vs. responsive) clonotype diversity, V(D)J usage profiles and V-J combinations from ESRD patients and to investigate the correlation between these features and EPO treatment efficacy. Results: Our results revealed statistical significance in the top 3 ~ 15 most abundant joint distributions of Vβ/Jβ among the two groups, suggesting the importance of V or J gene utilization in the EPO response of ESRD patients. Conclusions: In summary, we provided evidence addressing the potential correlation between the immune repertoire and EPO response in ESRD patients. Trial registration: TMU-JIRB 201309026. Registered 16 October 2013.",
keywords = "End-stage renal disease, Erythropoietin treatment, High-throughput sequencing, T-cell receptor repertoire",
author = "Chang, {Wei Chiao} and Wong, {Henry Sung Ching} and Chang, {Che Mai} and Kao, {Chih Chin} and Hsu, {Yu Wen} and Xiao Liu and Chang, {Wen Chang} and Wu, {Mai Szu}",
year = "2017",
month = "7",
day = "11",
doi = "10.1186/s12929-017-0349-5",
language = "English",
volume = "24",
journal = "Journal of Biomedical Science",
issn = "1021-7770",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - V-J combinations of T-cell receptor predict responses to erythropoietin in end-stage renal disease patients

AU - Chang, Wei Chiao

AU - Wong, Henry Sung Ching

AU - Chang, Che Mai

AU - Kao, Chih Chin

AU - Hsu, Yu Wen

AU - Liu, Xiao

AU - Chang, Wen Chang

AU - Wu, Mai Szu

PY - 2017/7/11

Y1 - 2017/7/11

N2 - Background: Anemia is common among end-stage renal disease (ESRD) patients who undergone hemodialysis. The total reduction of red blood cell (RBC) count is associated with poor prognosis in these patients. Although erythropoietin (EPO) has been used as an effective treatment for ESRD patients with anemia, a large number of patients still present poor responses to EPO treatment. Methods: We measured T-cell receptor sequencing profiles, including length of complementarity-deteremining region 3 (CDR3), intra- and inter-group (EPO resistant vs. responsive) clonotype diversity, V(D)J usage profiles and V-J combinations from ESRD patients and to investigate the correlation between these features and EPO treatment efficacy. Results: Our results revealed statistical significance in the top 3 ~ 15 most abundant joint distributions of Vβ/Jβ among the two groups, suggesting the importance of V or J gene utilization in the EPO response of ESRD patients. Conclusions: In summary, we provided evidence addressing the potential correlation between the immune repertoire and EPO response in ESRD patients. Trial registration: TMU-JIRB 201309026. Registered 16 October 2013.

AB - Background: Anemia is common among end-stage renal disease (ESRD) patients who undergone hemodialysis. The total reduction of red blood cell (RBC) count is associated with poor prognosis in these patients. Although erythropoietin (EPO) has been used as an effective treatment for ESRD patients with anemia, a large number of patients still present poor responses to EPO treatment. Methods: We measured T-cell receptor sequencing profiles, including length of complementarity-deteremining region 3 (CDR3), intra- and inter-group (EPO resistant vs. responsive) clonotype diversity, V(D)J usage profiles and V-J combinations from ESRD patients and to investigate the correlation between these features and EPO treatment efficacy. Results: Our results revealed statistical significance in the top 3 ~ 15 most abundant joint distributions of Vβ/Jβ among the two groups, suggesting the importance of V or J gene utilization in the EPO response of ESRD patients. Conclusions: In summary, we provided evidence addressing the potential correlation between the immune repertoire and EPO response in ESRD patients. Trial registration: TMU-JIRB 201309026. Registered 16 October 2013.

KW - End-stage renal disease

KW - Erythropoietin treatment

KW - High-throughput sequencing

KW - T-cell receptor repertoire

UR - http://www.scopus.com/inward/record.url?scp=85022321055&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85022321055&partnerID=8YFLogxK

U2 - 10.1186/s12929-017-0349-5

DO - 10.1186/s12929-017-0349-5

M3 - Article

VL - 24

JO - Journal of Biomedical Science

JF - Journal of Biomedical Science

SN - 1021-7770

IS - 1

M1 - 43

ER -